Ann: Production commenced to support 6000 Australian Patients, page-26

THC will be targeting 6,000 Australian patients representing an estimated annualised revenue of $20 million.

THC Global will supply medicinal cannabis medicines under the Canndeo brandTHC Global Group Ltd (ASX:THC) has received an expanded commercial cultivation permit and has commenced production towards the supply of medicinal cannabis medicines to an initial 6,000 Australian patients.Under the law, cultivation includes all steps up to, but not including, harvest.

The company will exercise the permit at the cultivation facility located in Bundaberg, Queensland, as well as associated research permits and licence amendments.

The Bundaberg growing site consists of 6.6 hectares of hydroponic greenhouses.This will support at least an initial 3,000 patients with 100% Australian medicinal cannabis.

The medicinal cannabis will be supplied direct to pharmacies, clinics and hospitals, meeting the requirements of Australia’s Narcotic Drugs Act and Regulations.With Australian patients currently paying from $300 to $600 per month for their legal cannabis medicines, this market is a good revenue opportunity for the company.

.“Our complete control of cannabis biomass, manufacturing, supply, and support will help achieve this.“We expect to supply at least an initial 6,000 patients using Canndeo medicinal cannabis on an ongoing basis commencing from Q2 2020.“Further Australian patients and global exports will follow.

$20 million dollars from Aussie + revenue from Canada and NZ and ???? is a tidy sum of
coming their way, and yours.